Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 349-357

  Bergvall, Niklas ^a   Tambour, Magnus ^b   Henriksson, Freddie ^b   Fredrikson, Sten ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Sweden   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cost minimization; Costs; Fingolimod; Multiple sclerosis; Natalizumab; Sweden

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

ARTICLE; CONSULTATION; COST CONTROL; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; LEISURE; MEDICAL FEE; MULTIPLE SCLEROSIS; PATIENT MONITORING; SWEDEN;

ANTIBODIES, MONOCLONAL, HUMANIZED; COST OF ILLNESS; COSTS AND COST ANALYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; SWEDEN;

EID: 84873925758     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.755537     Document Type: Article

References (37)

1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
3. Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011;17:901-8
4. Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
5. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
6. Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
7. Buchanan R, Huang C. Health-related quality of life among informal caregivers assisting people with multiple sclerosis. Disabil Rehabil 2011;33:113-21
8. Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 2010;10:433-40
9. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
10. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(2 Suppl):S96-104
11. Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13
12. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
13. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-85
14. Clar C, Velasco Garrido M, Gericke C, et al. Interferons and natalizumab for multiple sclerosis. GMS Health Technol Assess 2008;4:Doc09
15. Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009;16:420-3
16. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;(4):CD002002
17. FDA. Fingolimod (Gilenya) Prescribing and Labeling Information: latest label approved on 20/07/2011. 2011 http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/022527s002lbl.pdf. [Last accessed March 8, 2012]
18. EMA. Gilenya summary of product characteristics. 2012 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002202/WC500104528.pdf. [Last accessed August 20, 2012]
19. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
20. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular inter-feron for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
21. TLV. Price database of reimbursed drugs. 2012. http://www.tlv.se/beslut/ sok/lakemedel. [Last accessed April 4, 2012]
22. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011;17:708-19
23. O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
24. Nixon R, Eckert B, Cutter G, et al., editors. Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relap-sing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY. ENS: 22nd meeting of the European Neurological Society 2012; Prague, Czech Republic, 9-12 June 2012
25. EMA. Assessment report Gilenya (fingolimod). 2011. http://www.ema.euro- pa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002202/ WC500104529.pdf. [Last accessed March 8, 2012]
26. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). TLV; 2003. http://www.tlv.se/Upload/English/ENG- lfnar-2003-2.pdf. [Last accessed July 19, 2012]
27. The Pharmaceutical Benefits Board. EMA. Tysabri summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000603/WC500044686.pdf. [Last accessed March 8, 2012]
28. Swedish MS Society. Gilenya guidelines. 2011. http://mssallskapet.se/ SMSSrekGilenya.pdf. [Last accessed December 10, 2012]
29. Swedish MS Society. Tysabri guidelines. 2011. http://mssallskapet.se/ rektysabri.pdf. [Last accessed December 10, 2012]
30. EMA. Questions and answers on the review of Gilenya: outcome of a procedure under Article 20 of Regulation (EC) No 726/2004. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2012/04/ WC500125689.pdf. [Last accessed December 10, 2012]
31. Gold R, Kappos L, Palace J, et al., editors. Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multi-centre FIRST study in relapsing multiple sclerosis patients. ENS: 22nd meeting of the European Neurology Society; 2012; Prague, Czech Republic, 9-12 June 2012
32. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natali-zumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
33. Grytten Torkildsen N, Lie SA, Aarseth JH, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008;14:1191-8
34. Statistics Sweden. Life tables for Swedish population. 2004-2008. http://www.scb.se/Pages/ProductTables-25795.aspx. [Last accessed April 10, 2011]
35. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
36. TLV. Decision on Tysabri. 2012. www.tlv.se/Upload/Beslut-2006/BES-061222- tysabri.pdf. [Last accessed April 4, 2012]
37. DiMarco JP, O'Connor P, Cohen JA, et al., editors. First-dose effect of fingo-limod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS). ECTRIMS: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010; Gothenburg, Sweden